Supplementary Material - Cancer Research
Supplementary MaterialPathway crosstalk quantification reveals synergistic drug combinations for breast cancerSamira Jaeger1, Ana Igea1, Rodrigo Arroyo1, Victor Alcalde1, Bego?a Canovas1, Modesto Orozco1, 2, Angel R. Nebreda1, 3 and Patrick Aloy1,3*S1 Experimental validation of drug combinations in human cancer cell linesS1.1 Cell lines and culture conditionsThe validation of selected drug combinations was conducted in five human cancer cell lines: four breast cancer cell lines, namely MCF-7, MDA-MB-231, SKBR3 and BT-474 representing distinct breast cancer subtypes. In addition, we also included U2OS, as a typical cancer cell line derived from bone osteosarcoma. An overview on molecular characteristics of each cell line is shown in Figure 4A.MCF-7 and MDA-MB-231 cells were kindly provided by Dr. Violeta Serra (VHIO, Barcelona, Spain). U2OS cells were kindly provided by Dr. Travis Stracker (IRB, Barcelona, Spain). BT-474 cells were kindly provided by Dr. Roger Gomis (IRB, Barcelona, Spain). All cell lines were tested for mycoplasma contamination.Monolayers of all cell lines were cultured in flasks (VWR Tissue Culture Flask, USA). MCF-7 cells were maintained in DMEM medium (Gibco, Germany) supplemented with 10% (v/v) fetal bovine serum (Gibco, Germany) and 1% of Penicillin-Streptomycin (Gibco, Germany). U2OS and SKBR3 cell lines were maintained in the same conditions, but also incorporated 1% L-glutamine (Sigma-Aldrich, Germany). MDA-MB-231 and BT-474 cells were cultured in DMEM/F12 medium (Gibco, Germany) supplemented with 10% (v/v) fetal bovine serum (Gibco, Germany) and 1% of Penicillin-Streptomycin (Gibco, Germany), and for BT-474 cells 1% L-glutamine (Sigma-Aldrich, Germany) was incorporated. All cell lines were incubated at 37°C in a humidified atmosphere containing 5% CO2. Cells were passaged using Trypsin/EDTA 1x (Sigma-Aldrich, Germany) either every 3 days (MDA-MB-231, MCF-7 and U2OS) or twice a week (BT-474 and SKBR3).S1.2 DrugsDrugs were purchased from Selleckchem (USA), Tocris Bioscience (UK) and Roche (Switzerland) and stock solutions were prepared as indicated by the provider using either DMSO or water as dissolvent. Drug sensitivity was tested at four concentrations, selected according to data from previous studies in which the same compounds have been used in similar conditions. Table S2 shows the specific details for each compound tested (name, supplier and CAS number) as well as the experimental conditions used (solvent, stock solution prepared, the four doses used and the incubation time in which each drug was tested) and the references used to determine the drug doses.S1.3 Cell viability – MTT assayTo measure drug sensitivity we used the MTT assay, a colorimetric assay which reflects the mitochondrial activity of living cells based on their ability to reduce tetrazolium dye, MTT, to insoluble formazan crystals ADDIN EN.CITE <EndNote><Cite><Author>van Meerloo</Author><Year>2011</Year><RecNum>37</RecNum><DisplayText>(1)</DisplayText><record><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431333961">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>van Meerloo, J.</author><author>Kaspers, G. J.</author><author>Cloos, J.</author></authors></contributors><auth-address>Department of Paediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands.</auth-address><titles><title>Cell sensitivity assays: the MTT assay</title><secondary-title>Methods Mol Biol</secondary-title></titles><periodical><full-title>Methods Mol Biol</full-title></periodical><pages>237-45</pages><volume>731</volume><edition>2011/04/26</edition><keywords><keyword>Cell Culture Techniques</keyword><keyword>Cell Line</keyword><keyword>Cytotoxins/*toxicity</keyword><keyword>Drug Toxicity/pathology</keyword><keyword>Formazans/chemistry/metabolism</keyword><keyword>Humans</keyword><keyword>Tetrazolium Salts/*metabolism</keyword><keyword>Thiazoles/*metabolism</keyword><keyword>Toxicity Tests/*methods</keyword></keywords><dates><year>2011</year></dates><isbn>1940-6029 (Electronic)
1064-3745 (Linking)</isbn><accession-num>21516412</accession-num><urls><related-urls><url>;(1). The concentration of solubilized formazan can be determined by measuring the optical density (OD) using a plate reader. Since the mitochondrial activity is typically constant in viable cells, an increase or decrease in the activity correlates linearly with the number of viable cells. For drug sensitivity measurements, the OD values of cells treated with drugs are commonly compared to the OD of untreated cells.Prior to the experiments, the optimal cell density was assessed to ensure exponential growth of cells at days 3 or 5 in 96-well micro-culture plates in conditions of low serum culture used for the experiments (see Table S7).Cells were seeded in 96-well plates at the respective densities in 100 μL per well. After overnight incubation, the corresponding drugs were added to the cell cultures at one of the four doses. In the case of combined treatments, both drugs were added simultaneously and cells were exposed continuously to the drugs. Cells were incubated at 37?C in a humidified atmosphere with 5% CO2 for the exposure intervals specified in Table S2 (3 or 5 days). At that time, 20 μL of MTT (Sigma; 5 mg/mL in PBS) were added to each well, and the plates were incubated for 3 h at 37°C. Then, the supernatant was aspirated, 100 μL of DMSO was added to each well and absorbance was measured at 570 nm.Experiments were performed either in triplicates (individual drugs) or quadruplicates (drug combinations) and repeated three independent times. Cell survival is expressed as cell growth relative to the growth of control cells, that is, absorbance of treated well / absorbance of untreated control. Survival values were averaged across the experiments and standard deviation was obtained.S2 Impact of the residual standard error (RSE)To determine the ICX values for a given inhibition level X for individual drugs and combinations, we used the drc R package ADDIN EN.CITE <EndNote><Cite><Author>Ritz</Author><Year>2005</Year><RecNum>63</RecNum><DisplayText>(2)</DisplayText><record><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431333962">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ritz, C.</author><author>Streibig, J. C.</author></authors></contributors><titles><title>Bioassay analysis using R</title><secondary-title>Journal of Statistical Software</secondary-title></titles><periodical><full-title>Journal of Statistical Software</full-title></periodical><volume>12</volume><number>5</number><dates><year>2005</year></dates><urls></urls></record></Cite></EndNote>(2). As indicated in the main manuscript, in some instances, the estimated ICX corresponds to a value beyond the tested concentration range. Two cases in which the IC50 is either considerably close or far from the maximum concentration tested are illustrated in Supplementary Fig. S14. The IC50 derived for cabozantinib is 15.27 μM with the maximum concentration being 15 μM (Supplementary Table S2). Given the experimental data and the modeled dose-response curve shown in Supplementary Fig. S14A, the value is likely to present a reliable IC50. In contrast, the IC50 for trastuzumab is 176.72 μg/mL (Supplementary Fig. S14B), which is far beyond the maximum concentration of 40 μg/mL (Table S2). Considering the respective dose-response curve, it is not evident whether a proliferation inhibition of 50% will be reached at all.If a single agent does not reach a pre-defined inhibition level, we assume that the contribution of this agent to the combination is marginal, i.e., CD1,X = 0 or CD2,X = 0 ADDIN EN.CITE <EndNote><Cite><Author>Miller</Author><Year>2013</Year><RecNum>25</RecNum><DisplayText>(3)</DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431333961">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Miller, M. L.</author><author>Molinelli, E. J.</author><author>Nair, J. S.</author><author>Sheikh, T.</author><author>Samy, R.</author><author>Jing, X.</author><author>He, Q.</author><author>Korkut, A.</author><author>Crago, A. M.</author><author>Singer, S.</author><author>Schwartz, G. K.</author><author>Sander, C.</author></authors></contributors><auth-address>1Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</auth-address><titles><title>Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets</title><secondary-title>Sci Signal</secondary-title></titles><periodical><full-title>Sci Signal</full-title></periodical><pages>ra85</pages><volume>6</volume><number>294</number><edition>2013/09/26</edition><dates><year>2013</year><pub-dates><date>Sep 24</date></pub-dates></dates><isbn>1937-9145 (Electronic)</isbn><accession-num>24065146</accession-num><urls><related-urls><url> [pii]
10.1126/scisignal.2004014</electronic-resource-num><language>eng</language></record></Cite></EndNote>(3). However, including or omitting an IC50 value might have significant consequences for the drug combination index (DCI), with respect to synergy and antagonism in general, but also on the degree of such a drug interaction. For instance, assuming that the contribution of cabozantinib to the combination is negligible results in a DCI50 of 0.22 indicating strong synergism between the two drugs. However, the drug-response curves show that the effect is at best slightly synergistic or even additive (Supplementary Fig. S14A). In turn, when accepting the IC50 of 15.27 μM, we yield a DCI50 of 0.912 reflecting near additivity as anticipated by visual inspection of the dose-response curves. Note that such an effect might be even more pronounced if the combination reaches the IC50 while the individual agents both have an IC50, which is closely beyond the maximum concentration. In this case, the DCI indicates very strong synergy (DCI50 = 0) but the true drug interaction might even be antagonistic. In the case of trastuzumab in DC09 (Supplementary Fig. S14B), the effect is less distinct. Here, the DCI50 only changes from 0.66 to 0.79 (synergy to modest synergy) when neglecting or considering the IC50 of this agent, respectively.To obtain more reasonable DCIs, we tried to discriminate IC50 that are outside of the concentration range but provide likely a reliable measure by using the relative standard error (RSE) that can be obtained from the standard error associated with each ICX estimate. We applied a threshold of 0.15 assuming that IC values with a RSE below this value are acceptable. The RSE for cabozantinib in DC06 is 0.04, thus we consider the IC50 to be reliable when calculating the DCI50. In turn, the RSE of trastuzumab is 0.5 indicating that the IC50 estimate is not reliable. Table S5 shows that without considering the RSE when determining the IC50, we are likely to overestimate the degree of synergy of combinations. However, when considering an error margin of 0.15 we yield more realistic DCIs.S3 In vivo xenograft modelS3.1 Animals Mice were housed according to national and EU regulation and protocols were approved by the animal care and use committee of Parc Cientific Barcelona.Five-week-old athymic nude female mice (Harlan Laboratories) were anesthetized using i.p. injections of ketamine (750 mg/kg body weight)/xylazine (50 mg/kg body weight). Six days prior to cell injection a 0.18-mg 17β-estradiol 60-day release pellet (Innovative Research of America, Saratosa, FL) was implanted subcutaneously.MCF-7 cells were grown in monolayer and were harvested during the exponential growth phase (less than 80% confluence) using trypsin, suspended in a 1:1 PBS:Matrigel (BD Biosciences) mixture and kept on ice. For orthotopic injections, mice were surgically incised and a pocket was created using forceps until the mammary gland was available. Cell suspension was gently agitated to prevent the cells from settling and fifty microliters (1x106 cells) were immediately injected into the mammary gland using a 21G needle. Animals were placed in a clean cage and observed for 10-15 minutes to ensure recovery from the anesthetic. Tumors were observable about 1 month after injection.S3.2 Treatment ProtocolTumors were allowed to reach around 120-150 mm3 before the start of the treatment. Animals with tumors in the proper size range were randomly divided into the various treatment groups. We used 39 mice with two tumors per group (3 initial tumors; 9 control; 9 raloxifene; 9 cabozantinib, and 9 combination of raloxifene and cabozantinib). Animals were treated with compounds once daily by i.p. and/or oral gavage for a total of 15 days. Compounds were administered using as vehicle 30% PEG-400, 20% propylene glycol and 50% distilled water, and were given by exact body weight, with the injection volume being 0.1 ml/10 g body weight. Tumor growth was determined by caliper measurement (mm) and using the formula (LengthxWidth2)/2=mm3. Tumor size and animal weight were determined every two days.S3.3 Immunohistochemistry assaysTumors were excised at day 15, fixed in formalin and embedded in paraffin. Five-micron-thick sections of formalin fixed, paraffin embedded tissue were prepared from all tumors.Sections were deparaffinized, re-hydrated, and then subjected to antigen retrieval using the DAKO citrate retrieval (DAKO; Carpinteria, CA). Hematoxylin and eosin (H&E) stained sections of tumors were compared. To determine cell proliferation, sections were stained with an antibody against Ki67 (Novocastra), using as secondary antibody HRP conjugated anti-rabbit (ImmunoLogic). The signal was visualized with diaminobenzidine peroxidase and counterstained with hematoxylin. Stained sections were analyzed by manually counting cell nuclei positive for Ki67 staining; a minimum of three fields (20x) for each xenograft tumor was counted and the mean count per field was calculated.To detect apoptosis, sections were deparaffinized, re-hydrated and treated according to the “In situ Cell Death Detection Kit, Fluorescein” (Roche). A minimum of five images per group was taken, the positive area was calculated using ImageJ for each tumor and average values for each group were plotted.S3.4 PCI assessment at molecular level and Western blot protocolTo assess pathway crosstalk inhibition for DC02 on the molecular level, we identified proteins involved in pathway crosstalk predicted to be modulated predominantly by the combination, including Akt, Src and the nuclear form of the estrogen receptor (nER), and analyzed their activity using western blots in the tumor samples (Fig. 6E/F). Akt and Src modulation were assessed directly by means of their phosphorylation status (phospho-Akt, phospho-Src), which determines the activity of those proteins. Selecting Src and Akt also allows for the evaluation of the modulation of a signaling axis (Src—Pi3k—Akt), which is part of the full pathway crosstalk network (see Fig. 6E). In the case of nER, we measured the total levels of Cyclin D1 as a read out of the activity of nER for which Cyclin D1 is a well-characterized target gene. We focused on nER as it can be activated in a ligand-independent manner through MEK and ERK ADDIN EN.CITE <EndNote><Cite><Author>Heldring</Author><Year>2007</Year><RecNum>81</RecNum><DisplayText>(4)</DisplayText><record><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431603651">81</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Heldring, N.</author><author>Pike, A.</author><author>Andersson, S.</author><author>Matthews, J.</author><author>Cheng, G.</author><author>Hartman, J.</author><author>Tujague, M.</author><author>Strom, A.</author><author>Treuter, E.</author><author>Warner, M.</author><author>Gustafsson, J. A.</author></authors></contributors><auth-address>Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.</auth-address><titles><title>Estrogen receptors: how do they signal and what are their targets</title><secondary-title>Physiol Rev</secondary-title></titles><periodical><full-title>Physiol Rev</full-title></periodical><pages>905-31</pages><volume>87</volume><number>3</number><keywords><keyword>Animals</keyword><keyword>Estrogens/chemistry/pharmacology</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Protein Isoforms</keyword><keyword>Receptors, Estrogen/antagonists & inhibitors/*metabolism</keyword><keyword>*Signal Transduction</keyword></keywords><dates><year>2007</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0031-9333 (Print)
0031-9333 (Linking)</isbn><accession-num>17615392</accession-num><urls><related-urls><url>;(4). Samples from MCF-7 xenografts were lysed in 50?mM Tris–HCl pH 7.5, 150?mM NaCl, 1mM DTT, 1% NP-40, 5?mM EDTA, 5?mM EGTA, 20?mM NaF, 0.1?mM sodium orthovanadate, 1?μM microcystin and the Protease Inhibitor Cocktail Set III from Merck Millipore. Total lysates were centrifuged for 15min at 16,000?×?g?and 4°C and supernatants were quantified using the Protein Assay kit (Bio-Rad). Proteins (30?μg) were separated by SDS–PAGE and transferred to nitrocellulose membranes (Protran, Schleicher & Schuell) using the Trans-well Blot? system (Bio-Rad). Membranes were blocked with 5% non-fat dry milk in PBS for 1 hour at RT and then incubated with the following antibodies: phospho-AKT (9271 Cell Signaling), BCL2 (2870 Cell Signaling), phospho-SRC (05-677 Millipore), Cyclin D1 (8396 Santa Cruz Biotechnologies) and alpha-Tubulin (T9026 Sigma Aldrich).All primary antibodies were diluted 1:1000 in 2% BSA, except for tubulin that were diluted 1:5000, and were visualized using the Odyssey Infrared Imaging System (Li-Cor, Biosciences) using with Alexa Fluor 680/800-conjugated secondary antibodies (Molecular Probes).S4 Functional relationships among KEGG pathwaysTo assess crosstalk across all pathways in the KEGG database, we obtained 293 human pathways from the KEGG database from which we removed drug metabolism (2) and disease pathways (67), yielding in total a set of 224 pathways. Pathways have been retrieved from KEGG using the REST-style KEGG API.We assessed the functional relationships among different pathway sets in two ways: (1) all KEGG pathways, as well as (2) pathways from clinical combinations and (3) pathways from predicted drug combinations, by (A) considering shared genes/proteins among pathway pairs as well as by (B) computing pathway crosstalk. Supplementary Fig. S3A shows that pathway pairs from the complete KEGG set have a significantly lower protein overlap than pathway pairs from clinical and predicted combinations (p-value < 2.2e-16). Predicted combinations show a significant higher protein overlap compared to pathway pairs from clinical combinations (p-value = 0.011). Note that a high overlap of genes/proteins denotes not only functional similarity between pathways but might also indicate functional redundancy, which, in turn, may induce alternative signaling and crosstalk. For assessing pathway crosstalk, we excluded 113 pathways (mostly metabolic pathways), which do not comprise protein-protein interactions, but only protein-compound interactions and enzyme-enzyme relations. When considering crosstalk between pathway pairs in the three pathway sets (Supplementary Fig. S3B), we observe a similar trend as for shared pathway components (Supplementary Fig. S3A). A higher pathway crosstalk can be detected between pairs from clinical (mean: 0.11) and predicted combinations (mean: 0.097) compared to all KEGG pathways (mean: 0.059) with protein interactions (p-value < 2.2e-16). Pathways combined in clinical combinations exhibit a higher crosstalk compared to pathways from predicted combinations with a p-value = 0.0002814.S5 Efficacy of clinically relevant drug combinations with respect to the PCITo assess whether there are differences between combinations passing the PCI threshold of 0.34 and those failing it, we collected information regarding efficacy and clinical benefit of each combination, if available, from () as well as from the literature, to classify each combination with respect to its clinical benefit. Given the available information, we classified the 86 combinations into “with” (32), “without” (22) and “unknown” clinical benefit (32). The number of combinations above (34 of 54) and below (20 of 32) the pathway crosstalk inhibition threshold of 0.34 is shown in Supplementary Fig. S4A. The fraction of combinations with unknown clinical benefit is equally distributed across both sets, with 37% (20/54) and 37.5% (12/32) for PCI ≥ 0.34 and PCI < 0.34, respectively. Given the available clinical annotations, we observe a weak but statistically significant difference (p-value = 0.03215) between the PCI of combinations with and without proven clinical benefit (Supplementary Fig. S4B), indicating that combinations passing the PCI threshold of 0.34 are more likely to be have a clinical benefit compared to combinations failing this threshold.Note that in general the information regarding the efficacy of a combination is often not easily accessible, difficult to interpret or preliminary as trials are ongoing. Furthermore, trial conditions differ significantly; certain combinations fail for a particular subtype or setting (metastatic vs. early breast cancer, heavily pretreated vs. prevention of recurrence), but might still be effective under different conditions, yet to be tested. On the other hand, a number of combinations is only in early (safety) phases, such as Phase 1/1b trials, lacking information regarding their therapeutic efficacy. Given the challenge of assessing the success of clinical combinations under the distinct trial conditions, we decided to consider the 86 combinations in our analysis.S6 Enrichment of synergistic combinations in comparison with high-throughput experimental screensConsidering the experimental data from the drug screening performed by Miller et al ADDIN EN.CITE <EndNote><Cite><Author>Miller</Author><Year>2013</Year><RecNum>25</RecNum><DisplayText>(3)</DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431333961">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Miller, M. L.</author><author>Molinelli, E. J.</author><author>Nair, J. S.</author><author>Sheikh, T.</author><author>Samy, R.</author><author>Jing, X.</author><author>He, Q.</author><author>Korkut, A.</author><author>Crago, A. M.</author><author>Singer, S.</author><author>Schwartz, G. K.</author><author>Sander, C.</author></authors></contributors><auth-address>1Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</auth-address><titles><title>Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets</title><secondary-title>Sci Signal</secondary-title></titles><periodical><full-title>Sci Signal</full-title></periodical><pages>ra85</pages><volume>6</volume><number>294</number><edition>2013/09/26</edition><dates><year>2013</year><pub-dates><date>Sep 24</date></pub-dates></dates><isbn>1937-9145 (Electronic)</isbn><accession-num>24065146</accession-num><urls><related-urls><url> [pii]
10.1126/scisignal.2004014</electronic-resource-num><language>eng</language></record></Cite></EndNote>(3) we assessed the statistical significance of the enrichment of synergistic combinations obtained by our method. This data set presents with 14.3% one of the higher rates of detected synergistic combinations published in the literature. Based on the information of 91 drug combinations obtained among 14 targeted compounds screened in a tumor-derived liposarcoma cell line (DDLS817), we performed a random sampling of a) 50 combinations, b) 40 combinations and c) 10 combinations. Those samplings reflect the 50 drug combinations tested in all five human cancer cell lines, 40 combinations in the four breast cancer cell lines, and 10 combinations in the individual cell lines.For each sampling we determined the number of synergistic combinations as well as the percentage of synergistic drug combinations. We repeated the sampling N=10,000 times to generate a sampling distribution from which we then computed an empirical p-value to assess the statistical significance of the synergy rates obtained by our method.Figure S8 illustrates the outcomes of this assessment. Overall, 32% of the drug combinations tested showed synergy (Figure 4B). This number increase up-to 35% when considering only breast cancer cell lines. Sampling 50 combinations 10,00 times from the high-throughput data set, yields on average 14.3% of synergistic drug combinations (median of 14%), while sampling 40 combinations yields a synergy rate of 14.3% (median of 15%). Figure S8A and S8B show that both synergy rates obtained from the random sampling are significantly smaller than the ones obtained by our method (p-value < 1e-04). Considering the 10 drug combinations for each individual cell line, 50% of the combinations in MCF-7 and SKBR3 and 20% of the combinations in MDA-MB-231, BT-474 and U2OS are synergistic (see Figure 4B). Sampling 10 combinations 10,000 times from Millers data set, results in an average synergy rate of 14.4% (median 10%). Thus, the enrichment of synergistic combinations achieved by means of our method in MCF-7 and SKBR3 is highly significant (p-value = 5e-04, Figure S7C). Although the enrichment of synergistic combinations detected in MDA-MB-231, BT-474 and U2OS is higher than observed for the random sampling (20% vs. 14.4%), this enrichment is not significant (p-value = 0.15, Figure S8C). This shows that the enrichment of synergistic drug combinations identified by our method compared to the high-throughput screen without computational prioritization of Miller et al. is statistically significant.SUPPLEMENTARY INFORMATION: TABLESSupplementary Table S1: Complete list of breast cancer drugs (Excel table).Supplementary Table S2: Information about the breast cancer drugs tested in combination and the conditions in which the experiments were performed. NameSupplierCAS numberSolventStock Solution (nM)Concentration rangeIncubation time (h)ReferencesD01Cabozantinib (XL-184)Selleckchem849217-68-1DMSO205 / 7,5 / 10 / 15 μM72, 120PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWdlPC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48UmVj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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWdlPC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48UmVj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 EN.CITE.DATA (5)D02Dinaciclib(SCH727965)Selleckchem779353-01-4DMSO10,5 / 5 / 10 / 50 nM72 ADDIN EN.CITE <EndNote><Cite><Author>Feldmann</Author><Year>2011</Year><RecNum>8</RecNum><DisplayText>(6)</DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="axx0rvv0x2rpd9etfvyp9wpkd2z2vtf2z5s5" timestamp="1409649532">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Feldmann, Georg</author><author>Mishra, Anjali</author><author>Bisht, Savita</author><author>Karikari, Collins</author><author>Garrido-Laguna, Ignacio</author><author>Rasheed, Zeshaan</author><author>Ottenhof, NIki A.</author><author>Dadon, Tikva</author><author>Alvarez, Hector</author><author>Fendrich, Volker</author><author>Rajeshkumar, N. V.</author><author>Matsui, William</author><author>Brossart, Peter</author><author>Hidalgo, Manuel</author><author>Bannerji, Rajat</author><author>Maitra, Anirban</author><author>Nelkin, Barry D.</author></authors></contributors><titles><title>Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models</title><secondary-title>Cancer Biology & Therapy</secondary-title></titles><periodical><full-title>Cancer Biology & Therapy</full-title></periodical><pages>598-609</pages><volume>12</volume><number>7</number><dates><year>2011</year></dates><publisher>Landes Bioscience Inc.</publisher><urls><related-urls><url>;(6)D03ErlotinibSelleckchem183321-74-6DMSO50,5 / 1 / 7,5 / 15 μM72 ADDIN EN.CITE <EndNote><Cite><Author>Yamasaki</Author><Year>2007</Year><RecNum>9</RecNum><DisplayText>(7)</DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="axx0rvv0x2rpd9etfvyp9wpkd2z2vtf2z5s5" timestamp="1409649532">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Yamasaki, Fumiyuki</author><author>Zhang, Dongwei</author><author>Bartholomeusz, Chandra</author><author>Sudo, Tamotsu</author><author>Hortobagyi, Gabriel N.</author><author>Kurisu, Kaoru</author><author>Ueno, Naoto T.</author></authors></contributors><titles><title>Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity</title><secondary-title>Molecular Cancer Therapeutics</secondary-title></titles><periodical><full-title>Molecular Cancer Therapeutics</full-title></periodical><pages>2168-2177</pages><volume>6</volume><number>8</number><dates><year>2007</year><pub-dates><date>August 1, 2007</date></pub-dates></dates><urls><related-urls><url>;(7)D04NVP-AEW541(~Figitumumab)Selleckchem475489-16-8DMSO205 / 7,5 / 10 / 15 μM72PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYXJjw61hLUVjaGV2ZXJyw61hPC9BdXRob3I+PFllYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYXJjw61hLUVjaGV2ZXJyw61hPC9BdXRob3I+PFllYXI+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ADDIN EN.CITE.DATA (8,9)D05Trastuzumab(Herceptin)Roche180288-69-1Water20 mg/ml5 / 10 / 20 / 40 μg/mL72PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MdTwvQXV0aG9yPjxZZWFyPjIwMDE8L1llYXI+PFJlY051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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MdTwvQXV0aG9yPjxZZWFyPjIwMDE8L1llYXI+PFJlY051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 EN.CITE.DATA (10-12)D06Paclitaxel(Taxol)Selleckchem33069-62-4DMSO200,1 / 1 / 7,5 / 15 μM72PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYW5nPC9BdXRob3I+PFllYXI+MjAwNTwvWWVhcj48UmVj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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYW5nPC9BdXRob3I+PFllYXI+MjAwNTwvWWVhcj48UmVj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=
ADDIN EN.CITE.DATA (13,14)D07Midostaurin(PKC412)Tocris120685-11-2DMSO100,1 / 0,5 / 1 /10 μM72 ADDIN EN.CITE <EndNote><Cite><Author>Tenzer</Author><Year>2001</Year><RecNum>17</RecNum><DisplayText>(15)</DisplayText><record><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="axx0rvv0x2rpd9etfvyp9wpkd2z2vtf2z5s5" timestamp="1409649532">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Tenzer, Angela</author><author>Zingg, Daniel</author><author>Rocha, Sonia</author><author>Hemmings, Brian</author><author>Fabbro, Doriano</author><author>Glanzmann, Christoph</author><author>Schubiger, P. August</author><author>Bodis, Stephan</author><author>Pruschy, Martin</author></authors></contributors><titles><title>The Phosphatidylinositide 3?€?-Kinase/Akt Survival Pathway Is a Target for the Anticancer and Radiosensitizing Agent PKC412, an Inhibitor of Protein Kinase C</title><secondary-title>Cancer Research</secondary-title></titles><periodical><full-title>Cancer Research</full-title></periodical><pages>8203-8210</pages><volume>61</volume><number>22</number><dates><year>2001</year><pub-dates><date>November 15, 2001</date></pub-dates></dates><urls><related-urls><url>;(15)D08Olaparib(AZD2281)Selleckchem763113-22-0DMSO200,01 / 0,1 / 1 / 5 μM72, 120PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYXN0YWs8L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYXN0YWs8L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxS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ADDIN EN.CITE.DATA (16-18)D09PD-0332991(Palbociclib)Selleckchem571190-30-2Water40,01 / 0,1 / 0,5 / 5 μM72, 120PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaXU8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxSZWNO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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaXU8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxSZWNO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ADDIN EN.CITE.DATA (19,20)D10RaloxifeneSelleckchem84449-90-1DMSO200,1 / 1 / 10 / 20 μM72PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GcnlhcjwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJl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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GcnlhcjwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJl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==
ADDIN EN.CITE.DATA (21,22)D11Tanespimycin(17-AAG)Selleckchem75747-14-7DMSO20,2 / 2 / 20 / 200 nM72PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HdW88L0F1dGhvcj48WWVhcj4yMDA1PC9ZZWFyPjxSZWNO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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HdW88L0F1dGhvcj48WWVhcj4yMDA1PC9ZZWFyPjxSZWNO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ADDIN EN.CITE.DATA (23,24)Supplementary Table S3: Scheme for refining the degrees of synergy or antagonism ADDIN EN.CITE <EndNote><Cite><Author>Chou</Author><Year>2006</Year><RecNum>39</RecNum><DisplayText>(25)</DisplayText><record><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431333961">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Chou, T. C.</author></authors></contributors><auth-address>Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. chout@</auth-address><titles><title>Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies</title><secondary-title>Pharmacol Rev</secondary-title><alt-title>Pharmacological reviews</alt-title></titles><periodical><full-title>Pharmacol Rev</full-title><abbr-1>Pharmacological reviews</abbr-1></periodical><alt-periodical><full-title>Pharmacol Rev</full-title><abbr-1>Pharmacological reviews</abbr-1></alt-periodical><pages>621-81</pages><volume>58</volume><number>3</number><edition>2006/09/14</edition><keywords><keyword>Algorithms</keyword><keyword>Animals</keyword><keyword>Automatic Data Processing</keyword><keyword>*Computer Simulation</keyword><keyword>Dose-Response Relationship, Drug</keyword><keyword>*Drug Antagonism</keyword><keyword>*Drug Combinations</keyword><keyword>*Drug Synergism</keyword><keyword>Humans</keyword><keyword>Medical Informatics</keyword><keyword>Models, Biological</keyword><keyword>Models, Theoretical</keyword><keyword>*Research Design</keyword><keyword>Software</keyword><keyword>Statistics as Topic</keyword></keywords><dates><year>2006</year><pub-dates><date>Sep</date></pub-dates></dates><isbn>0031-6997 (Print)
0031-6997 (Linking)</isbn><accession-num>16968952</accession-num><work-type>Review</work-type><urls><related-urls><url>;(25).Effect typeDCI rangeDescriptionSynergy< 0.1Very strong synergism– 0.3Strong synergism0.3 – 0.7Synergism0.7 – 0.85Moderate synergismAdditivity0.85 – 0.9Slight synergism0.9 – 1.1Nearly additive1.1 – 1.2Slight antagonismAntagonism1.2 – 1.45Moderate antagonism1.45 – 3.3Antagonism3.3 – 10Strong antagonism>10Very strong antagonismSupplementary Table S4: Impact of using the RSE for assessing the reliability of IC50s beyond the maximum concentration on the number of synergistic combinations. RSESynergistic(DCI ≤ 0.85)Additive (0.85 > DCI ≤ 1.2)Antagonistic(DCI > 1.2)Combinations w/o DCI0.0040%26%10%24%0.0538%32%12%18%0.1034%38%14%14%0.1532%38%16%14%Supplementary Table S5: Overview on the predicted drug combinations together with the pathways mainly involved in crosstalk inhibition (Excel table).Supplementary Table S6: Treatment indication of the individual drugs for a certain breast cancer subtype, if clear treatment details are available. Underline drugs have been approved for breast cancer while the other drugs are under investigation (HR+ Hormone receptor positive breast cancer; HER2+ HER2-overexpressing breast cancer; TN Triple negative breast cancer; SERM Selective estrogen receptor modulator).Drug classSubtype treatment indicationCabozantinibVEGFR inhibitorHR+ breast cancerErlotinibEGFR inhibitorTN breast cancerRaloxifeneSERMHR+ breast cancerOlaparibPARP-1 inhibitorTN breast cancerDinaciclibCDK inhibitor?TanespimycinHSP inhibitorHER2+ breast cancerPaclitaxelMicrotubule modulatorMetastatic (all subtypes)PD-0332991CDK inhibitorHR+ breast cancerTrastuzumabHER2 inhibitorHER2+ breast cancerFigitumumabIGF-1R inhibitorHR+ breast cancerSupplementary Table S7: Number of cells seeded for each cell line and depending on MTT conditions.MDA-MB-231MCF-7SKBR3BT-474U2OS3-day MTT4,0002,5005,0005,0002,5005-day MTT1,5001,0002,5002,5001,000SUPPLEMENTARY INFORMATION: FIGURESSupplementary Figure S1: Overview on currently combined drug classes clinically tested (according to a drug’s therapeutic targets, see Supplementary Table S1). The size of each circle represents the number of combinations between two classes. For instance, instance EGFR inhibitors and microtubule inhibitors are frequently combined with each other, while other drug class combinations are not exploited at all. Drug classes marked with an asterisk are formed by subclasses with differing targets. AI - aromatase inhibitors, CDKi – CDK inhibitors, DI – agents directly interfering with the DNA, EGFRi – EGFR and ERBB2 inhibitors, HSPi – heat shock protein inhibitors, MM – microtubule modulators, MRKi – multiple receptor kinase inhibitors, mTORi – mTOR and PI3K inhibitors, PARPi – PARP inhibitors, SERM – selective estrogen receptor modulators, Various – various inhibitors.Supplementary Figure S2: Illustration of the drug combination index (DCI) for an inhibition level of 50%. The dose-response curves for individual drugs, paclitaxel and tanespimycin, are shown in green and blue, respectively. The combination is shown in black. Concentrations of the individual drugs were selected from the literature to hit their activity range (Table S2); see additional PDF S6 for dose-response curves of all ten combinations in the five cell lines.Supplementary Figure S3: Functional relationships between pathways in terms of (A) shared proteins and (B) pathway crosstalk (using the Jaccard similarity coefficient). All – human pathways from KEGG, CC – pathways from clinical combinations, Predicted – pathways from predicted combinations. Asterisks ‘*’,’**’ and ‘***’ indicate p-values below 0.05, 0.01 and 0.001, respectively.Supplementary Figure S4: Evaluation of clinical drug combinations with respect to the available clinical annotations indicating improved efficacy and/or clinical benefit. A) Number of combinations above (54) and below (32) the pathway crosstalk inhibition (PCI) threshold, distinguishing between combinations with and without clinical annotations. B) Comparison of the PCI values obtained for combination “with” and “without” confirmed clinical benefit. The ‘*’ indicates a p-value below 0.05, here p-value = 0.03215.Supplementary Figure S5: Correlation of the drug combination index (DCI) with the PCI computed for drug combinations between 14 targeted screened in a liposarcoma cell line ADDIN EN.CITE <EndNote><Cite><Author>Miller</Author><Year>2013</Year><RecNum>25</RecNum><DisplayText>(3)</DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wsxvz5peg0t9pre0ft2xxtfdrx9fz2ax2s0e" timestamp="1431333961">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Miller, M. L.</author><author>Molinelli, E. J.</author><author>Nair, J. S.</author><author>Sheikh, T.</author><author>Samy, R.</author><author>Jing, X.</author><author>He, Q.</author><author>Korkut, A.</author><author>Crago, A. M.</author><author>Singer, S.</author><author>Schwartz, G. K.</author><author>Sander, C.</author></authors></contributors><auth-address>1Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</auth-address><titles><title>Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets</title><secondary-title>Sci Signal</secondary-title></titles><periodical><full-title>Sci Signal</full-title></periodical><pages>ra85</pages><volume>6</volume><number>294</number><edition>2013/09/26</edition><dates><year>2013</year><pub-dates><date>Sep 24</date></pub-dates></dates><isbn>1937-9145 (Electronic)</isbn><accession-num>24065146</accession-num><urls><related-urls><url> [pii]
10.1126/scisignal.2004014</electronic-resource-num><language>eng</language></record></Cite></EndNote>(3) (Pearson correlation coefficient = -0.439, p-value = 0.0001829). Supplementary Figure S6: Enrichment of clinically relevant and non-tested combinations at different pathway crosstalk inhibition values. The difference between the two groups of combinations is shown in gray.Supplementary Figure S7: Sigmoid-fitted dose-response curves generated for each of the experimentally validated drug combinations in the five cell lines (additional PDF). Note that for some combinations we could not fit the dose-response curves, thus they are not shown in the additional PDF.Supplementary Figure S8:Assessment of the statistical significance of the different synergy rates obtained in (A) five cancer cell lines (32%), (B) four breast cancer cell lines (35%) and (C) each cell line (50% for MCF-7 and SKBR3; and 20% for MDA-MB-231, BT-474, U2OS).Supplementary Figure S9: Overview on the DCI50 per drug combination. The green area represents synergy (DCI ≤ 0.85) while yellow indicates additivity (0.85 > DCI ≤ 1.2). Combinations having a DCI above 1.2 are antagonistic. Note that the DCI50 for combination DC08 is 70.27, but we set it to 3.5 for a better visualization.Supplementary Figure S10: Drug combination index of the combinations summarized per cell line. The green area represents synergy (DCI ≤ 0.85) while yellow indicates additivity (0.85 > DCI ≤ 1.2). Combinations having with a DCI above 1.2 are antagonistic. The DCI50 for combination DC08 in MDA-MB-231 cells is 70.27, but has been set to 3.5 for a better visualization.Supplementary Figure S11: Overview on the interaction behavior of each combination across the five cell lines. (A) Cells are colored according to the median DCI value determined for inhibition levels of 20 to 80%. C indicates consistent behavior (i.e. neither synergistic-antagonistic nor additive-antagonistic shifts). CCL depicts the proportion of consistent combinations per cell line while CDC specifies the percentage of consistent cell lines per combination. (B) Distribution of DCI values ranging from 20 to 80% of proliferation inhibition (IC20 to IC80), illustrated exemplarily for drug combination DC02; see additional PDF S13 for the distribution of DCI20 to DCI80 of all combinations.Supplementary Figure S12: Effects of individual and combinatorial treatment on body weight. Animal weights were recorded every two days.Supplementary Figure S13: Distribution of DCI values (DCI20 to DCI80) ranging from 20 to 80% of proliferation inhibition (IC20 to IC80) for DC01 to DC10 (additional PDF).Supplementary Figure S14:Illustration of two instances in which the estimated IC50 is beyond the maximum concentration tested (indicated with a ‘*’). (A) In the case of cabozantinib in DC06, the IC50 of 15.27 μM is considered to be reliable as it is only slightly larger than the maximum concentration (15 μM) with a low RSE. (B) For trastuzumab in DC09, the IC50 of 176.72 μg/mL is far beyond the highest concentration of 40 μg/mL. The RSE of 0.5 indicates that this estimate is unlikely to be reliable.REFERENCES ADDIN EN.REFLIST 1.van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011;731:237-45.2.Ritz C, Streibig JC. Bioassay analysis using R. Journal of Statistical Software 2005;12(5).3.Miller ML, Molinelli EJ, Nair JS, Sheikh T, Samy R, Jing X, et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal 2013;6(294):ra85.4.Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87(3):905-31.5.Hage C, Rausch V, Giese N, Giese T, Schonsiegel F, Labsch S, et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013;4:e627.6.Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology & Therapy 2011;12(7):598-609.7.Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Molecular Cancer Therapeutics 2007;6(8):2168-77.8.García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541?€”A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5(3):231-39.9.Hartog H, Vand Der Graaf WTA, Boezen HM, Wesseling J. Treatment of Breast Cancer Cells by IGF1R Tyrosine Kinase Inhibitor Combined with Conventional Systemic Drugs. Anticancer Research 2012;32(4):1309-18.10.Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). Journal of the National Cancer Institute 2001;93(24):1852-57.11.Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007;6(7):2065-72.12.Shattuck DL, Miller JK, Carraway KL, Sweeney C. Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. Cancer Research 2008;68(5):1471-77.13.Wang Z, Goulet R, Stanton KJ, Sadaria M, Nakshatri H. Differential Effect of Anti-apoptotic Genes Bcl-xL and c-FLIP on Sensitivity of MCF-7 Breast Cancer Cells to Paclitaxel and Docetaxel. Anticancer Research 2005;25(3C):2367-79.14.Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol 2009;34(2):313-9.15.Tenzer A, Zingg D, Rocha S, Hemmings B, Fabbro D, Glanzmann C, et al. The Phosphatidylinositide 3?€?-Kinase/Akt Survival Pathway Is a Target for the Anticancer and Radiosensitizing Agent PKC412, an Inhibitor of Protein Kinase C. Cancer Research 2001;61(22):8203-10.16.Hastak K, Alli E, Ford JM. Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin. Cancer Research 2010;70(20):7970-80.17.Min A, Im S-A, Yoon Y-K, Song S-H, Nam H-J, Hur H-S, et al. RAD51C-deficient cancer cells are highly sensitive to the poly (ADP-ribose) polymerase inhibitor, olaparib. Molecular Cancer Therapeutics 2012.18.Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells. Molecular Cancer Research 2012;11(2):140-48.19.Liu F, Korc M. Cdk4/6 Inhibition Induces Epithelial?€“Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells. Molecular Cancer Therapeutics 2012;11(10):2138-48.20.Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast cancer research : BCR 2009;11(5):R77.21.Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, et al. Raloxifene Attenuation of 5-FU/Methotrexate Cytotoxicity in Human Breast Cancer Cells: The Importance of Sequence in Combination Chemotherapy. Anticancer Research 2006;26(3A):1861-67.22.Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003;95(21):1586-97.23.Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition. Cancer Research 2005;65(21):10006-15.24.Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, et al. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biology & Therapy 2008;7(10):1630-40.25.Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews 2006;58(3):621-81. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- new cancer research treatments
- advances in cancer research submission
- advances in cancer research journal
- new cancer research breakthroughs
- cancer research donation page
- breast cancer research foundation
- cancer research submission guidelines
- national cancer research foundation scam
- american association for cancer research 2020
- american association for cancer research foundation
- material science research topics
- cancer research companies